Characterization of the CCR5 chemokine receptor gene

Biochemistry and Molecular Biology Education

Volumn 32, Issue 3, 2004, Pages 191-195

  Thomas, John C ^a  

^a UNIVERSITY OF MICHIGAN DEARBORN   (United States)

Author keywords

Cell biology; Cytokine receptor; Genetics; HIV 1

Indexed keywords

CHEMOKINE RECEPTOR CCR5;

ALLELE; ARTICLE; CYTOLOGY; DNA ISOLATION; GENE AMPLIFICATION; GENE FUNCTION; GENE IDENTIFICATION; GENE STRUCTURE; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PROTEIN FUNCTION; PROTEIN STRUCTURE; RETROVIRUS; VIRUS ADSORPTION; WILD TYPE;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; UNIDENTIFIED RETROVIRUS;

EID: 2642544149     PISSN: 14708175     EISSN: None     Source Type: Journal    
DOI: 10.1002/bmb.2004.494032030357     Document Type: Article

References (14)

1. C, Blanpain, F. Libert, G. Vassart, M. Parmentier (2002) CCR5 and HIV infection, Receptors Channels 8, 19-31.
2. J. P. Moore, A. Trkola, T. Dragic (1997) Co-receptors for HIV-1 entry, Curr. Opin. Immunology 9, 551-562.
3. Y. Cao, L. Qin, L, Zhang, J. Safrit, D. Ho (1995) Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type I infection, N. Engl. J. Med. 332, 201-208.
4. M. Samson, F. Libert, B. J. Doranz, J. Rucker, C. Liesnard, C. M. Farber, S. Saragosti, C. Lapoumeroulie, J. Cognaux, C. Forceille, G. Muyldermans, C. Verhofstede, G. Burtonboy, M. Georges, T. Imai, S. Rana, Y. Yi, R. J. Smyth, R. G. Collman, R. W. Doms, G. Vassart, M. Parmentier. (1996) Resistance to HIV-1 infection in Caucasian individuals bearing the mutant alleles of the CCR-5 chemokine receptor gene, Nature 382, 722-725.
5. R. Liu, W. A. Paxton, S. Choe, D. Ceradini, S. R. Martin, R. Horuk, M. E. MacDonald, H. Stuhlmann, R. A. Koup, N. R. Landau (1996) Homozygous defect in HIV-1 coreceptor accounts for resistance in some multiply-exposed individuals to HIV-1 infection, Cell 86, 367-377.
6. Y. Huang, W. Paxton, S. M. Wolinsky, A. Neumann, L. Zhang, T. He, S. Kang, D. Ceradini, Z. Jin, K. Yazdanbakhsh, K. Kunstman, D. Erickson, E. Dragon, N. R. Landau, J. Phair, D. Ho, R. A. Koup (1996) The role of a mutant CCR5 allele in HIV-1 transmission and disease progression, Nat. Med. 2, 1240-1243.
7. J. M. McNicholl, D. K. Smith, S. H. Qari, T. Hodge (1997) Host genes and HIV: The role of the chemokine receptor gene CCR5 and its allele (delta 32), Emerg. Infect. Dis. 3, 261-271.
8. M. T. Rugeles, F. Solano, F. J. Diaz, V. I. Bedoya, P. J. Patiño (2002) Molecular characterization of the CCR5 gene in seronegative individuals exposed to human immunodeficiency virus (HIV), J. Clin. Virol. 23, 161-169.
9. J. J. Martinson, N. H. Chapman, D. C. Rees, Y. T. Liu, J. B. Clegg (1997) Global distribution of the CCR5 gene 32-bp deletion, Nat. Genet. 16, 100-103.
10. N. S. Yudin, S. V. Vinogradov, T. A. Potapova, T. M. Naykova, V. V. Sitnikova, I. V. Kulikov, V. W. Khasnulin, C. Konchuk, P. E. Vloschinskii, S. V. Ivanov, V. F. Kobzev, A. G. Romaschenko, M. I. Voevoda (1998) Distribution of CCR5-D32 gene deletion across the Russian part of Eurasia, Hum. Genet. 102, 695-698.
11. R. McGinnis, F. Child, S. Clayton, S. Davies, W. Lenney, T. Illig, M. Wjst, N. Spurr, C. Debouck, A. H. Hajeer, W. E. Ollier, R. Strange, A. A. Fryer (2002) Further support for the association of CCR5 allelic variants with asthma susceptibility, Eur. J. Immunogenet. 29, 525-528.
12. J. C. Thomas, R. Khoury, C. Neeley, A. M. Akroush, E. C. Davies (1997) A fast CTAB method of human DNA isolation for polymerase chain reaction applications, Biochem. Educ. 24, 233-235.
13. Y. Lin, C. Mettling, P. Portales, J. Reynes, J. Clot, P. Corbeau (2002) Cell surface CCR5 density determines the postentry efficiency of R5 HIV-1 infection, Proc. Natl. Acad. Sci. U. S. A. 99, 15590-15595.
14. F. W. Wit, R. P. Van Rij, G. J. Weverling, J. M. Lange, H. Schuitemaker (2002) CC chemokine receptor 5 delta32 and CC chemokine receptor 2 641 polymorphisms do not influence the virologic and immunologic response to antiretroviral combination therapy in human immunodeficiency virus type 1-infected patients, J. Infect. Dis. 186, 1726-1732.